Skip to content

A clinical study on precise intervention of ocular uric acid based on metabonomics for diabetic retinopathy

A clinical study on precise intervention of ocular uric acid based on metabonomics for diabetic retinopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036866
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

2:benzene bromine Malone
3:Febuxostat

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent and complying with study assessments throughout the study period; 2. Aged >=18 years; 3. Type I/II diabetes; 4. PDR Extensive retinal hemorrhage, exudation, neovascularization membrane and fibrogenesis were observed in the fundus, with/without retinal detachment, vitreous blood accumulation. It was determined that further treatment through surgery was needed; 5. The diagnosis of hyperuricemia (HUA) was defined as fasting serum uric acid level of >420 mol/L (i.e. 7mg/dl) in men and >357 mol/L (i.e. 5.95mg/dl) in women under normal purine diet not measured twice on the same day; 6. Glomerular filtration rate (GFR) >60 ml/min.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation; 2. Any other conditions that researchers believe would cause significant harm to the subjects; 3. Participate in another medical investigation or trial within 30 days; 4. Acute cardiovascular events requiring hospitalization in the past 3 months; 5. History of total retinal photocoagulation 3 months before or YAG cystectomy 1 month before; 6. Intravitreal steroid or periocular steroid therapy during the first 3 months; 7. History of vitrectomy in the eyes; 8. History of retinal detachment in the eye; 9. Previous trabeculectomy or other filtration surgery; 10. Active eye or periocular infection in both eyes; 11. History of any other retinal vascular disease in the eye (e.g., retinal vein occlusion, retinal artery occlusion); 12. History of any other retinal diseases other than diabetic retinopathy (e.g., AMD, hereditary retinal diseases).

Design outcomes

Primary

MeasureTime frame
Vitreous and serum levels of uric acid;

Countries

China

Contacts

Public ContactKun Liu

Shanghai General Hospital

drliukun@sjtu.edu.cn+86 021-63240090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026